Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
Burden
Fatigability
Fatigue
Impact
Myasthenia gravis
Qualitative research
Symptoms
Treatment
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
19
05
2022
accepted:
16
09
2022
pubmed:
3
11
2022
medline:
3
11
2022
entrez:
2
11
2022
Statut:
ppublish
Résumé
Patients with generalized myasthenia gravis (gMG) experience functional impairment due to MG symptoms. This study aimed to assess, from the patient perspective, the symptoms, impacts, and treatment goals of individuals diagnosed with gMG. Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States. Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant. The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%). Nearly all participants (96%) reported fluctuations in symptoms and severity. Participants' most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%). Impacts on physical functioning included an inability to participate in hobbies/sports, need for increased planning, and difficulties performing activities of daily living. All participants reported emotional impacts and impacts on their work and finances. Their treatment goals included reduced fatigue and weakness, improved symptom stability, and minimization of the impact of symptoms, in particular the emotional impact. The fluctuating and unpredictable nature of gMG symptoms was found to have a substantial impact on patients' emotional, social, and economic well-being. Participants' goals for symptom management suggest that greater focus is needed to help them quickly resume a normal lifestyle by achieving symptom stability. Impacts of fluctuating and unpredictable symptoms are difficult to measure, but it is important to consider symptom fluctuation as well as ongoing symptomatology when making treatment decisions, and to recognize the impact of uncontrolled symptoms on patients, their partners/caregivers, and family/friends. These factors are often not reflected in burden/cost-of-illness studies. The aim of this study was to understand—from the patient’s point of view—the range of generalized myasthenia gravis (gMG) symptoms that they experience, which symptoms bother them most, and which symptoms have the greatest impact on everyday life, as well as patients’ treatment goals. Researchers asked these questions in one-on-one interviews with 28 people in the US who have gMG. Study participants reported living with symptoms that come and go, and are sometimes severe, making it difficult to lead a normal life. The most frequently reported symptoms were eyelid drooping (reported by 93% of study participants), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%). The symptoms that bothered patients most were difficulties with vision (43%), problems breathing (36%), all-over fatigue (36%), and trouble swallowing (29%). Participants reported that gMG symptoms affected physical functioning, making it hard to participate in hobbies/sports, increasing the amount of planning needed to conduct their daily lives, and hindering their ability to do day-to-day activities (like driving, eating, and bathing). All participants reported that they were affected emotionally, and that the symptoms of gMG impacted their ability to work and their financial well-being. Participants’ treatment goals included reducing fatigue and weakness, making symptoms more stable, and reducing the impact of symptoms, particularly emotional impacts. These responses reveal the extensive effects of gMG symptoms on patients’ daily lives and highlight that symptom stability is especially important to people with gMG.
Autres résumés
Type: plain-language-summary
(eng)
The aim of this study was to understand—from the patient’s point of view—the range of generalized myasthenia gravis (gMG) symptoms that they experience, which symptoms bother them most, and which symptoms have the greatest impact on everyday life, as well as patients’ treatment goals. Researchers asked these questions in one-on-one interviews with 28 people in the US who have gMG. Study participants reported living with symptoms that come and go, and are sometimes severe, making it difficult to lead a normal life. The most frequently reported symptoms were eyelid drooping (reported by 93% of study participants), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%). The symptoms that bothered patients most were difficulties with vision (43%), problems breathing (36%), all-over fatigue (36%), and trouble swallowing (29%). Participants reported that gMG symptoms affected physical functioning, making it hard to participate in hobbies/sports, increasing the amount of planning needed to conduct their daily lives, and hindering their ability to do day-to-day activities (like driving, eating, and bathing). All participants reported that they were affected emotionally, and that the symptoms of gMG impacted their ability to work and their financial well-being. Participants’ treatment goals included reducing fatigue and weakness, making symptoms more stable, and reducing the impact of symptoms, particularly emotional impacts. These responses reveal the extensive effects of gMG symptoms on patients’ daily lives and highlight that symptom stability is especially important to people with gMG.
Identifiants
pubmed: 36322146
doi: 10.1007/s40120-022-00408-x
pii: 10.1007/s40120-022-00408-x
pmc: PMC9837342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107-128Informations de copyright
© 2022. The Author(s).
Références
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–54. https://doi.org/10.1172/jci29894 .
doi: 10.1172/jci29894
Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113–28. https://doi.org/10.1111/nyas.13522 .
doi: 10.1111/nyas.13522
Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473–94. https://doi.org/10.1007/s00415-016-8045-z .
doi: 10.1007/s00415-016-8045-z
Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66–71. https://doi.org/10.1159/000311012 .
doi: 10.1159/000311012
Westerberg E, Punga AR. Epidemiology of myasthenia gravis in Sweden 2006–2016. Brain Behav. 2020;10(11):e01819. https://doi.org/10.1002/brb3.1819 .
doi: 10.1002/brb3.1819
National Institute of Neurological Disorders and Stroke. Myasthenia gravis fact sheet. 2020. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet . Accessed 16 June 2021.
Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https://doi.org/10.1038/s41572-019-0079-y .
doi: 10.1038/s41572-019-0079-y
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. https://doi.org/10.1177/1756286419832242 .
doi: 10.1177/1756286419832242
Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10:2235. https://doi.org/10.3390/jcm10112235 .
doi: 10.3390/jcm10112235
Andersen LK, Jakobsson AS, Revsbech KL, Vissing J. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol. 2021;269:3086–93. https://doi.org/10.1007/s00415-021-10902-1 .
doi: 10.1007/s00415-021-10902-1
Petersson M, Feresiadou A, Jons D, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurology. 2021;97(14):e1382–91. https://doi.org/10.1212/wnl.0000000000012604 .
doi: 10.1212/wnl.0000000000012604
Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129. https://doi.org/10.1186/1477-7525-8-129 .
doi: 10.1186/1477-7525-8-129
Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2021;269:3050–63. https://doi.org/10.1007/s00415-021-10891-1 .
doi: 10.1007/s00415-021-10891-1
US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input . Accessed 30 June 2020.
US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients . Accessed 3 Mar 2022.
US Food and Drug Administration. CDER patient-focused drug development. 2022. https://www.fda.gov/drugs/development-approval-process-drugs/cder-patient-focused-drug-development . Accessed 3 Mar 2022.
Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. https://doi.org/10.1016/j.jval.2011.06.014 .
doi: 10.1016/j.jval.2011.06.014
Cheng KKF, Clark AM. Qualitative methods and patient-reported outcomes: measures development and adaptation. Int J Qual Methods. 2017;16(1):1609406917702983. https://doi.org/10.1177/1609406917702983 .
doi: 10.1177/1609406917702983
Strauss AL, Corbin JM. Basics of qualitative research: grounded theory procedures and techniques. Newbury Park: Sage Publications; 1990.
Creswell JW. Qualitative inquiry and research design: choosing among five approaches. Los Angeles: SAGE Publications; 2013.
Wolf JA, Niederhauser V, Marshburn D, LaVela SL. Defining patient experience. Patient Exp J. 2014;1(1):7–19.
Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487–9. https://doi.org/10.1212/wnl.52.7.1487 .
doi: 10.1212/wnl.52.7.1487
Assarroudi A, Heshmati Nabavi F, Armat M, Ebadi A, Vaismoradi M. Directed qualitative content analysis: the description and elaboration of its underpinning methods and data analysis process. J Res Nurs. 2018;23:42–55. https://doi.org/10.1177/1744987117741667 .
doi: 10.1177/1744987117741667
Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research: Princeton: Recording for the Blind & Dyslexic; 2008.
Corbin JM, Strauss AL. Basics of qualitative research: techniques and procedures for developing grounded theory. 3rd ed. Los Angeles: Sage Publications; 2009.
Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–42. https://doi.org/10.1016/j.jval.2017.11.014 .
doi: 10.1016/j.jval.2017.11.014
Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM. A conceptual framework for evaluating impairments in myasthenia gravis. PLoS ONE. 2014;9(5): e98089. https://doi.org/10.1371/journal.pone.0098089 .
doi: 10.1371/journal.pone.0098089
Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103–25. https://doi.org/10.1007/s40120-021-00285-w .
doi: 10.1007/s40120-021-00285-w
Frost A, Svendsen ML, Rahbek J, et al. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997–2011: a Danish nationwide cohort study. BMC Neurol. 2016;16(1):224. https://doi.org/10.1186/s12883-016-0757-2 .
doi: 10.1186/s12883-016-0757-2
Guastafierro E, Tramacere I, Toppo C, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54(4):304–12. https://doi.org/10.1159/000506310 .
doi: 10.1159/000506310
Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019;60(6):700–6. https://doi.org/10.1002/mus.26694 .
doi: 10.1002/mus.26694
Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2): e013278. https://doi.org/10.1136/bmjopen-2016-013278 .
doi: 10.1136/bmjopen-2016-013278
Mathers CD, Schofield DJ. The health consequences of unemployment: the evidence. Med J Aust. 1998;168(4):178–82. https://doi.org/10.5694/j.1326-5377.1998.tb126776.x .
doi: 10.5694/j.1326-5377.1998.tb126776.x
Voss M, Nylén L, Floderus B, Diderichsen F, Terry PD. Unemployment and early cause-specific mortality: a study based on the Swedish twin registry. Am J Public Health. 2004;94(12):2155–61. https://doi.org/10.2105/ajph.94.12.2155 .
doi: 10.2105/ajph.94.12.2155
Jin RL, Shah CP, Svoboda TJ. The impact of unemployment on health: a review of the evidence. CMAJ. 1995;153(5):529–40.
Modini M, Joyce S, Mykletun A, et al. The mental health benefits of employment: results of a systematic meta-review. Australas Psychiatry. 2016;24(4):331–6. https://doi.org/10.1177/1039856215618523 .
doi: 10.1177/1039856215618523
Waddell G, Burton K, Aylward M. Work and common health problems. J Insur Med. 2007;39(2):109–20.
Keer-Keer T. The lived experience of adults with myasthenia gravis: a phenomenological study. Australas J Neurosci. 2015;25(1):40–6. https://doi.org/10.21307/ajon-2017-112 .
Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014;50(4):493–500. https://doi.org/10.1002/mus.24213 .
doi: 10.1002/mus.24213
Harrington RL, Hanna ML, Oehrlein EM, et al. Defining patient engagement in research: results of a systematic review and analysis: report of the ISPOR Patient-Centered Special Interest Group. Value Health. 2020;23(6):677–88. https://doi.org/10.1016/j.jval.2020.01.019 .
doi: 10.1016/j.jval.2020.01.019